The OS number you were quoting for DcVaxL is still a blended number that includes the placebos; plus you might be quoting it from the 2018 JTM paper. It is almost 2022 now that OS must have improved quite a bit, imo. Stop fuding.
Simply not true!! Linda M Liau, MD, PhD, MBA June 13,2019
MGMT methylated median OS 35.1, 3 year survival 49.1% MGMT unmethylated median OS 19.8, 3 year survival 14.3%
SOC
In the methylated and unmethylated cohorts, they were 25.5 months (95% CI: 20.0–49.9) and 12.4 months (95% CI: 10.6–16.6), respectively. Comparing the KM curves, OS was significantly longer in the methylated versus unmethylated cohort (log rank p < 0.0001)
First, his abstract does not include number of patients with idh mutation that were methylated in placebo nor in treatment arm. Pretty much doomed if you don’t do that. Why would he doom his trial? He had plenty of time to read this abstract from 2016. Conclusions: While the importance of MGMT methylation is well established, we demonstrate that the combination of MGMT(methylated)/IDH1(+ve) is associated with considerably longer OS and PFS in this series of chemoradiotherapy-treated glioblastoma tumours. — 2016 . https://pubmed.ncbi.nlm.nih.gov/27526690/
Second, at this point, IDH-1 mutation is no longer considered GBM. The NWBO trial is likely to have had very idh-1 mutation patients in their trial for some reasons I don’t have time to go into this morning. Moreover, with the definition now changed, idh-mutation is likely excluded from the DCVax-l trial.
Third, mOS does not take long tail into consideration.
Fourth, the DCVax-l data is still blended.
I gotta be on the road, but there are numerous more reasons your comparison is bunk.
News 
Market Data 
Discover 
AI
